Literature DB >> 8850294

B-1 cells and their reactivity with the murine intestinal microflora.

F G Kroese1, R de Waard, N A Bos.   

Abstract

IgA secreting cells located in the lamina propria of the gut are a prominent feature of the mucosal immune system, which serves to protect the body from the continuous threat to infection by intestinal bacteria. In this review we summarize briefly the evidence that these IgA secreting cells have a dual origin and are derived either from conventional B cells or from B-1 cells. Furthermore, we show both at polyclonal and monoclonal levels that the major antigenic target of B-1 cell derived IgA are normal intestinal bacteria. Coating of intestinal bacteria with IgA is thought to result in immune exclusion, as shown for pathogenic bacteria. However, the bacterial microflora of the gut is an extremely stable ecosystem, despite the fact that the majority of intestinal bacteria are coated with IgA. We speculate here that these apparent contradictory functions of the humoral immune system, i.e. removal of bacteria and maintaining the normal gut flora might be exerted by IgA antibodies produced by the two B-cell lineages. The fixed and biased repertoire of B-1 cells might play a role in maintaining the normal intestinal flora. When pathogenic bacteria penetrate into the gut, conventional B cells may be induced in the Peyer's patches to produce high affinity, narrowly tuned IgA antibodies, leading to immune exclusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8850294     DOI: 10.1006/smim.1996.0003

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  34 in total

1.  Antibody repertoire development in fetal and newborn piglets, III. Colonization of the gastrointestinal tract selectively diversifies the preimmune repertoire in mucosal lymphoid tissues.

Authors:  J E Butler; J Sun; P Weber; P Navarro; D Francis
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

2.  Immunoglobulin A cell distribution in the human small intestine: phenotypic and functional characteristics.

Authors:  I N Farstad; H Carlsen; H C Morton; P Brandtzaeg
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

3.  Polyreactive antigen-binding B (PAB-) cells are widely distributed and the PAB population consists of both B-1+ and B-1- phenotypes.

Authors:  Z-H Zhou; A L Notkins
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

Review 4.  The role of secretory antibodies in infection immunity.

Authors:  Richard A Strugnell; Odilia L C Wijburg
Journal:  Nat Rev Microbiol       Date:  2010-08-09       Impact factor: 60.633

Review 5.  The double life of a B-1 cell: self-reactivity selects for protective effector functions.

Authors:  Nicole Baumgarth
Journal:  Nat Rev Immunol       Date:  2010-12-10       Impact factor: 53.106

Review 6.  Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion.

Authors:  Nicole Baumgarth; James W Tung; Leonore A Herzenberg
Journal:  Springer Semin Immunopathol       Date:  2005-01-05

7.  The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies.

Authors:  Zhao-Hua Zhou; Yahong Zhang; Ya-Fang Hu; Larry M Wahl; John O Cisar; Abner Louis Notkins
Journal:  Cell Host Microbe       Date:  2007-03-15       Impact factor: 21.023

Review 8.  Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases.

Authors:  Daniel A Peterson; Daniel N Frank; Norman R Pace; Jeffrey I Gordon
Journal:  Cell Host Microbe       Date:  2008-06-12       Impact factor: 21.023

9.  Intestinal IgA: novel views on its function in the defence of the largest mucosal surface.

Authors:  J Mestecky; M W Russell; C O Elson
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 10.  Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces.

Authors:  Jiri Mestecky; Michael W Russell
Journal:  Immunol Lett       Date:  2009-04-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.